ArticleBMC microbiology2026
Prophylactic and therapeutic efficacy of Acinetobacter phage RM_A1 against carbapenem-resistant Acinetobacter baumannii with no cytotoxicity to human skin cells.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rise in multidrug-resistant (MDR) bacteria has rendered common first- and last-line antibiotics ineffective, posing a serious threat to human health. Additionally, the global rise of wound infections caused by carbapenem-resistant Acinetobacter baumannii indicates that the “post-antibiotic” era has begun. Consequently, alternative antimicrobial therapies are urgently required, and the reuse of phages is a promising choice.
methodsTwenty-six strains of A. baumannii were isolated from wound-infected patients, identified by the Vitek 2 automated system, and confirmed by 16 S rDNA sequencing. The strains’ susceptibility to antibiotics and their ability to develop biofilms were then studied. Acinetobacter phage RM_A1 was isolated and characterized, and its lytic activity against A. baumannii was tested in vitro via time-killing curve and antibiofilm formation assays. The phage’s stability was also tested under various conditions. Genomic analysis was performed to characterize the phage and its virulence. Finally, the phage was assessed as a therapeutic and prophylactic agent against carbapenem-resistant A. baumannii in vitro by using human skin cells.
resultsThe clinical strains of A. baumannii were found to be resistant to the carbapenem antibiotics, exhibiting high MAR index values and a strong ability to form biofilm. The isolated RM-A1 phage had a myoviral morphology and a 43,994 bp double-stranded DNA genome encoding 84 open reading frames (ORFs), with no genes linked to antibiotic resistance or pathogenicity. This phage possesses a broad host range, with a lysis spectrum of 85% against clinical isolates. It also possesses a large burst size and a short adsorption rate. It was capable of withstanding temperatures as high as 90 °C, was pH-stable, and remained viable for 45 min when exposed to UV light. There was no significant drop in the vitality of HSF cells observed following phage treatment, proving that the phage is safe for use. In vitro results showed that the phage was able to inhibit and eliminate biofilm formation and significantly reduce bacterial growth.
conclusionOur research explores the potential use of RM_A1 phage as an alternative therapeutic agent for combating carbapenem-resistant A. baumannii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.